TreeFrog Therapeutics

TreeFrog Therapeutics is a private, pre-revenue biotech based in Bordeaux, France, operating at the intersection of cell therapy and regenerative medicine. The company's core innovation is the C-Stem™ platform, a scalable encapsulation technology designed to mass-produce high-quality induced pluripotent stem cell (iPSC)-derived therapies in a unique 3D microtissue format, which aims to improve cell survival, dosing, and safety. With a lead allogeneic cell therapy program for Parkinson's disease targeting a first-in-human trial in 2026 and a discovery program in liver disease, TreeFrog pursues a dual business model of advancing its own therapeutic pipeline while out-licensing its enabling C-Stem™ technology to partners. The company is well-capitalized, having raised significant funding, including a recent €30 million loan from the European Investment Bank, to scale its operations and technology.

C-Stem™: A proprietary, GMP-compliant, high-throughput biomimetic encapsulation platform that generates 3D microtissues for cell therapy. It enables scalable production (1000+ capsules/sec, 15B cells/batch) to improve cell survival, dose control, and quality.

TreeFrog competes in the rapidly evolving field of iPSC-derived allogeneic cell therapies, facing competition from both large biopharma and numerous agile biotechs. Its primary differentiation is the C-Stem™ platform's focus on scalable manufacturing and enhanced cell viability via 3D microtissues, a unique approach to solving critical industry bottlenecks.